Contact
searchSearch
HMP Global
Login

Breast Cancer Excellence Forum

Breast Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Sara Hurvitz, MD
Videos
PI3K Pathway Inhibition Improves Outcomes in Patients With Advanced Breast Cancer
05/08/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Sara Hurvitz, MD, discusses...
05/08/2026
Oncology
Paolo Tarantino, MD
Videos
Sacituzumab Govitecan Demonstrates Limited Activity Following T-DXd in HER2-Positive Metastatic Breast Cancer
05/07/2026
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses...
05/07/2026
Oncology
Sarah Premji, MD
Videos
Clinical Differences Among Oral SERDs in HR-Positive, HER2-Negative Breast Cancer
03/20/2026
Sarah Premji, MD
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses...
03/20/2026
Oncology
Sara Tolaney, MD
Videos
Sacituzumab Govitecan Plus Pembrolizumab in PD-L1-Positive Triple-Negative Breast Cancer
02/18/2026
Sara Tolaney, MD
Sara Tolaney, MD, discusses results from the phase 3 ASCENT-04 trial, assessing sacituzumab govitecan plus pembrolizumab in PD-L1–positive, locally advanced unresectable or metastatic triple-negative breast cancer.
Sara Tolaney, MD, discusses results from the phase 3 ASCENT-04 trial, assessing sacituzumab govitecan plus pembrolizumab in PD-L1–positive, locally advanced unresectable or metastatic triple-negative breast cancer.
Sara Tolaney, MD, discusses...
02/18/2026
Oncology
Sami Diab, MD
Videos
Updated NCCN Guidelines Strengthen Support for Breast Cancer Index® in Extended Endocrine Therapy Decision-Making
01/23/2026
Sami Diab, MD
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent...
01/23/2026
Oncology
Kelly McCann, MD, PhD, UCLA
Videos
Sequencing Antibody-Drug Conjugates Among Patients With Breast Cancer
09/18/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, discusses the sequencing of antibody-drug conjugates for patients with breast cancer.
Kelly McCann, MD, PhD, discusses the sequencing of antibody-drug conjugates for patients with breast cancer.
Kelly McCann, MD, PhD, discusses...
09/18/2025
Oncology
Heather Moore, CPP, PharmD, Duke Cancer Center
Videos
Managing Adverse Events for Patients With Breast Cancer
09/17/2025
Heather Moore, PharmD
Heather Moore, CPP, PharmD, discusses the management of adverse events for patients with breast cancer.
Heather Moore, CPP, PharmD, discusses the management of adverse events for patients with breast cancer.
Heather Moore, CPP, PharmD,...
09/17/2025
Oncology
Seth Wander, MD, PhD; Rachel Abelman, MD, Massachusetts General Brigham Cancer Center
Videos
Omitting Carboplatin from Neoadjuvant Regimen for Patients With HER2-Positive Early Breast Cancer
07/31/2025
Seth Wander, MD
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth...
07/31/2025
Oncology
Kelly McCann, Md, PhD, University of California, Los Angeles
Videos
Improving Abemaciclib Tolerability With a Dose Escalation Strategy for Early Stage HR-Positive, HER2-Negative Breast Cancer
06/11/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, shares insights on the results from the phase 2 TRADE study which evaluated the use of a dose escalation strategy for adjuvant abemaciclib to improve tolerability for patients with early-stage high-risk HR-positive,...
Kelly McCann, MD, PhD, shares insights on the results from the phase 2 TRADE study which evaluated the use of a dose escalation strategy for adjuvant abemaciclib to improve tolerability for patients with early-stage high-risk HR-positive,...
Kelly McCann, MD, PhD, shares...
06/11/2025
Oncology
Antonio Marra, MD, European Institute of Oncology
Videos
Prognostic Significance of Germline BRCA Status in HR-Positive, HER2-Negative Early Breast Cancer
06/10/2025
Antonio Marra, MD
Antonio Marra, MD, discusses the impact of germline BRCA status on distant relapse-free survival and invasive disease-free survival among patients with early HR-positive, HER2-negative breast cancer.
Antonio Marra, MD, discusses the impact of germline BRCA status on distant relapse-free survival and invasive disease-free survival among patients with early HR-positive, HER2-negative breast cancer.
Antonio Marra, MD, discusses the...
06/10/2025
Oncology

Recent News

News
National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer
09/29/2021
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national...
09/29/2021
Oncology
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
FDA Approval
FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications
05/07/2026
Stephanie Holland
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic...
05/07/2026
Oncology
FDA Alerts
Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer
05/07/2026
Stephanie Holland
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the...
05/07/2026
Oncology
News
Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Oligoprogression Predicts Improved Survival After Chemoimmunotherapy in Relapsed Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer
05/07/2026
Stephanie Holland
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2...
05/07/2026
Oncology
News
Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the...
05/07/2026
Oncology
News
ctDNA Dynamics to Predict Survival Outcomes in Patients With Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use